USPTO Art Unit 1618 Prosecution Statistics

Art Unit Information

Art Unit: 1618
Group: 1610
Tech Center: 1600
Total Cases: 13,829
Last Active: September 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19344588BRAND-NEW SKELETON 99MTC-FAPI DIAGNOSTIC PROBE AND USE THEREOF IN PREPARATION OF DRUG OR REAGENT FOR DIAGNOSING TUMORSSeptember 2025February 2026Allow510NoNo
19340137SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORSSeptember 2025January 2026Allow410NoNo
19324663MARINE ORGANISM INFUSED EFFERVESCENT TABLET FOR PRODUCING ENHANCED SUSPENSIONSSeptember 2025January 2026Allow401YesNo
19275155FORMULATIONS OF ANTI-INTERLEUKIN 1 RECEPTOR 1 ANTIBODIESJuly 2025November 2025Allow410NoNo
19268785INJECTABLE LEUCOVORIN FORMULATIONS AND METHODS OF PREPARING SAMEJuly 2025January 2026Allow611YesNo
19214841CATIONIC LIPIDS AND PREPARATION METHOD THEREOFMay 2025January 2026Allow800NoNo
19207162BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTSMay 2025December 2025Allow720NoNo
19204534GENE DELIVERY SYSTEM AND APPLICATION THEREOF IN PREPARATION OF DRUGS FOR TREATMENT OF TUMORSMay 2025January 2026Allow811NoNo
19184830PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64April 2025July 2025Allow300YesNo
19180813BIOORTHOGONAL COMPOSITIONSApril 2025December 2025Allow811YesNo
19178993NANOCARBON-IODINE CALCIUM ALGINATE MICROSPHERES AND PREPARATION METHOD AND APPLICATION THEREOFApril 2025October 2025Allow610NoNo
19176038PREVENTION OF ACCUMULATED TOLERANCE TO STIMULANT MEDICATION FOR THE TREATMENT OF ADHDApril 2025January 2026Allow910YesNo
19172351KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOFApril 2025August 2025Allow410NoNo
19092739NOVEL RIVAROXABAN FORMULATIONMarch 2025October 2025Allow710YesNo
19088446ORGANIC DENTAL DEVICE AND METHOD OF PREPARATION THEREOFMarch 2025July 2025Allow410NoNo
19080259METHOD OF INHIBITING CANCER CELL VIABILITYMarch 2025June 2025Allow300YesNo
19066754MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIESFebruary 2025August 2025Allow610NoNo
19063023BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTSFebruary 2025September 2025Allow710NoNo
19061632BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETINGFebruary 2025June 2025Allow400NoNo
19056537STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOFFebruary 2025August 2025Allow610YesNo
19045249BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTSFebruary 2025October 2025Allow820NoNo
19028880STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXESJanuary 2025December 2025Allow1121YesNo
19002144NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOFDecember 2024February 2026Allow1421YesNo
18983625GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGINGDecember 2024June 2025Allow610NoNo
18981276IMAGING COMPOUNDS FOR DETECTING OR IMAGING SENESCENT CELLSDecember 2024August 2025Allow820YesNo
18975168LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOFDecember 2024September 2025Abandon910NoNo
188719621,4-BIS-(2-HYDROXY-BENZYL)-1,4,7-TRIAZACYCLONONANE DERIVATIVES AND SIMILAR COMPOUNDS AS LIGANDS IN IRON(III) COMPLEXES FOR USE AS MRI CONTRAST AGENTSDecember 2024June 2025Allow601NoNo
18959449PARTICLE-CONTAINING DROPLET SYSTEMS WITH MONODISPERSE FLUID VOLUMESNovember 2024February 2026Abandon1520YesNo
18948808DUAL MODE RADIOTRACER AND-THERAPEUTICSNovember 2024September 2025Allow1020NoNo
18947606RADIOPHARMACEUTICALSNovember 2024July 2025Allow820YesNo
18931596RADIOPHARMACEUTICALS INCLUDING ENCAPSULATED GA+99mTcOctober 2024November 2025Allow1321NoNo
18932511NOVEL GENE DELIVERY AGENTSOctober 2024August 2025Allow911YesNo
18930419FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDESOctober 2024July 2025Allow911YesNo
18927034Stable, concentrated radionuclide complex solutionsOctober 2024February 2025Abandon400NoNo
18927058Stable, concentrated radionuclide complex solutionsOctober 2024August 2025Allow1001YesNo
18927047Stable, concentrated radionuclide complex solutionsOctober 2024May 2025Allow701YesNo
18917080PHARMACEUTICAL FORMULATIONS COMPRISING NALTREXONE AND/OR BUPROPIONOctober 2024April 2025Allow611YesNo
18915867HYDROXYAPATITE-ENCLOSED ZINC PHOSPHATE NANOCOMPOSITEOctober 2024December 2024Allow200YesNo
18909354Near-Infrared Dyes And Conjugates For Targeting TumorsOctober 2024September 2025Allow1110NoNo
18906805METHOD FOR CONVERTING ATRIAL FIBRILLATION TO SINUS RHYTHM WITH LOW-RISK, LOW-COST PROTOCOL, AND PREVENTING RECURRENCE OF ATRIAL FIBRILLATIONOctober 2024October 2025Allow1311YesNo
18905806FORMULATION OF EAR DROPS AND METHODS FOR DELIVERY THEREOF FOR TREATING UPPER RESPIRATORY INFECTIONSOctober 2024April 2025Allow611YesNo
18903882INJECTABLE FORMULATIONS OF PARP INHIBITORS AND USES THEREOFOctober 2024May 2025Allow721YesNo
18902113POLYMER NANOPARTICLE COMPOSITIONS FOR IN VIVO EXPRESSION OF POLYPEPTIDESSeptember 2024July 2025Allow911YesNo
18899589COMPOSITIONS AND METHODS OF TREATING MELANOMASeptember 2024January 2026Abandon1520NoNo
18819282METHOD OF TREATING CANCERAugust 2024October 2025Abandon1420NoNo
18812148RAPID FORMING ARTIFICIAL BLOOD VESSEL AND PREPARATION METHODAugust 2024November 2025Abandon1520NoNo
18811352PHARMACEUTICAL COMPOSITION WITH NANOPARTICLE-BASED DRUG DELIVERY COMBINED WITH NON-INVASIVE RADIOGRAPHIC MONITORING MODELAugust 2024February 2025Allow610NoNo
18807243SYSTEMS AND METHODS FOR FILLING VIALS WITH GASESAugust 2024October 2025Abandon1421NoNo
18805445CARBONIC ANHYDRASE IX-TARGETING RADIOACTIVE DIAGNOSTIC AND THERAPEUTIC MEDICAMENT AND METHOD FOR PREPARING SAMEAugust 2024October 2025Allow1530NoNo
18791270[177LU] LUTETIUM-PSMA I&T COMPOSITION AND DOSIMETRY, KIT, METHOD OF MAKING, AND METHOD OF USING THEREOFJuly 2024April 2025Allow920YesNo
18787389CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORSJuly 2024November 2025Allow1610YesNo
18780126MODIFIED FORMS OF AMBROXOL FOR THERAPEUTIC USEJuly 2024March 2026Allow2030NoNo
18776861PEPTIDE-UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOFJuly 2024June 2025Allow1121YesNo
18771562Structural Optimization Method to Improve the Theranostic Performance of Peptide Receptor-Targeted Radionuclide Therapy for CancersJuly 2024April 2025Allow920YesNo
18770529RADIOPHARMACEUTICAL COMPOSITION AND METHODSJuly 2024February 2025Allow711NoNo
18724324METHOD FOR CONSTRUCTING HYDROPHILIC ANTIFOULING COATING ON SURFACE OF MEDICAL IMPLANTABLE MATERIALJune 2024July 2025Allow1310NoNo
18751743PHOSPHOR-CONTAINING DRUG ACTIVATOR KITJune 2024September 2025Abandon1520NoNo
18750610STEM CELL-NANO DRUG DELIVERY SYSTEM COMPLEX, USE THEREOF AND METHOD FOR PREPARING THE SAMEJune 2024January 2026Allow1930NoNo
18750073RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGINGJune 2024August 2025Allow1411NoNo
18745896PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64June 2024March 2025Allow920YesNo
18745906COPPER-64 COMPOSITIONS AND FORMULATIONSJune 2024October 2024Allow400YesNo
18736211MASTIC-DERIVED NATURAL PROTECTANTSJune 2024August 2025Allow1410NoNo
18733537PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64June 2024August 2025Allow1430YesYes
18673805EMBOLIC COMPOSITIONS AND METHODSMay 2024March 2025Allow1011NoNo
18673814EMBOLIC COMPOSITIONS AND METHODSMay 2024March 2025Allow1011NoNo
18670587RADIOLABELED CANNABINOID RECEPTOR 2 LIGANDMay 2024January 2026Allow1910NoNo
18669670NEAR-INFRARED (NIR) ABSORBING PHOTOSENSITIZERSMay 2024January 2026Allow2011YesNo
18662569METHODS FOR DETECTING CCR2 RECEPTORSMay 2024August 2025Allow1611NoNo
18660867FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USESMay 2024July 2025Abandon1420NoNo
18655741COMPOSITION OF RADIOACTIVE AND NON-RADIOACTIVE MICROPARTICLESMay 2024November 2025Allow1810YesNo
18655248FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USESMay 2024October 2025Abandon1811NoNo
18706375EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOFApril 2024February 2026Abandon2100NoNo
18648498COMPOSITE ANTIBACTERIAL HYDROGEL DRESSING, PREPARATION METHOD AND APPLICATION THEREOFApril 2024September 2024Allow501NoNo
18646785RADIONUCLIDE LABELED POLYPEPTIDE CONJUGATES AND USES THEREOFApril 2024March 2025Allow1121NoNo
18646526MULTI-MODE IMAGING MARKERSApril 2024December 2024Allow700YesNo
18643088STABLE INTRAVENOUS DILTIAZEM HYDROCHLORIDE FORMULATION AND USE THEREOFApril 2024February 2025Allow1020YesNo
18640620COMBINATIONS OF IMAGING AGENT CONJUGATES AND APPLICATION THEREOFApril 2024March 2026Allow2331NoNo
18640169ZWITTERIONIC METAL CHELATORSApril 2024June 2025Allow1421YesNo
18640891Stable, concentrated radionuclide complex solutionsApril 2024October 2024Allow600YesNo
18640917Stable, concentrated radionuclide complex solutionsApril 2024October 2024Allow600YesNo
18640884Stable, concentrated radionuclide complex solutionsApril 2024September 2024Allow500YesNo
18640907Stable, concentrated radionuclide complex solutionsApril 2024October 2024Allow600YesNo
18640787CHITOSAN-HYBRIDIZED ZINC PHOSPHATE/HYDROXYAPATITE NANOSTRUCTURE-BASED DRUG DELIVERY SYSTEMApril 2024October 2024Allow610NoNo
18640730STABLE READY TO DILUTE COMPOSITION OF CARFILZOMIBApril 2024June 2025Allow1430NoNo
18637431NANOPARTICLES WITH NON-COVALENTLY BOUND TARGETING MOIETIES FOR USE IN A THERAPEUTIC METHOD AND FOR NON-MEDICAL USEApril 2024August 2025Abandon1621NoNo
18637037HYDROPHOBIC TOPICAL COMPOSITIONS AND METHODS FOR PRODUCING SAMEApril 2024January 2025Allow910NoNo
18629717MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOFApril 2024June 2025Allow1410NoNo
18625544Cationic Lipid Compound and Composition for Delivery of Nucleic Acids and Use ThereofApril 2024March 2025Allow1111YesNo
18625862MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIESApril 2024December 2024Allow810YesNo
18624706POLYOLS AND POLYOL-BASED HYDROGELS WITH ANTI-CANCER ACTIVITYApril 2024March 2025Allow1131NoNo
18623926THIN FILM INTERPOSITION OF BASEMENT MEMBRANE SCAFFOLDSApril 2024September 2025Allow1820NoNo
18621985LABELED OXYTOCIN AND METHOD OF MANUFACTURE AND USEMarch 2024July 2025Allow1510NoNo
18621526SUPRAMOLECULAR IONIZABLE LIPID MOLECULES WITH HETEROATOMIC TUNING FOR NUCLEIC ACID DELIVERYMarch 2024June 2025Allow1421YesNo
18618520COMPOSITIONS COMPRISING ATICAPRANTMarch 2024September 2024Allow510NoNo
18617245FORMULATION OF CONTRAST MEDIA AND PROCESS OF PREPARATION THEREOFMarch 2024November 2024Allow800YesNo
18615185LIQUID DOSAGE FORMS OF SODIUM NAPROXENMarch 2024March 2026Abandon2401NoNo
18614094RADIOPHARMACEUTICAL CONJUGATE COMPOUND FOR DIAGNOSIS AND/OR THERAPEUTIC USES THEREOFMarch 2024October 2025Allow1931YesNo
18612564LIPIDS AND COMPOSITIONS THEREOFMarch 2024January 2025Allow1010YesNo
18612430Formulations Of ApremilastMarch 2024March 2025Allow1210NoNo
18612370CONTROLLED RELEASE FORMULATIONS FOR THE TREATMENT OF MALARIAMarch 2024June 2025Abandon1410NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1618.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
551
Examiner Affirmed
375
(68.1%)
Examiner Reversed
176
(31.9%)
Reversal Percentile
47.8%
Lower than average

What This Means

With a 31.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
2163
Allowed After Appeal Filing
441
(20.4%)
Not Allowed After Appeal Filing
1722
(79.6%)
Filing Benefit Percentile
7.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1618 - Prosecution Statistics Summary

Executive Summary

Art Unit 1618 is part of Group 1610 in Technology Center 1600. This art unit has examined 13,829 patent applications in our dataset, with an overall allowance rate of 46.4%. Applications typically reach final disposition in approximately 41 months.

Comparative Analysis

Art Unit 1618's allowance rate of 46.4% places it in the 5% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1618 receive an average of 2.52 office actions before reaching final disposition (in the 88% percentile). The median prosecution time is 41 months (in the 10% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.